Fevzi Necati Avsar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fevzi Necati Avsar has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Tuncay Sahutoglu
Department of Nephrology, Mehmet Akif Inan Training and Research Hospital, Sanliurfa, Türkiye
2 shared publications - Döndü Şanlıtürk
Tokat Gaziosmanpaşa Üniversitesi Erbaa Sağlık Bilimleri Fakültesi
1 shared publication - Neslihan Dörtkardeş
Health Sciences University Mehmet Akıf Inan Training Research Hospital
1 shared publication Nihat Kılıcaslan
Sanliurfa Mehmet Akif Inan Training and Research Hospital, University of Health Sciences
1 shared publication- Osman Erinc
Department of Internal Medicine, Kanuni Sultan Suleyman Training and Research Hospital, 34303 Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 2 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0357671
Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study
Background: Interleukin-1 and interleukin-6 blockade have been widely used in severe COVID-19, but comparative real-world evidence regarding anakinra and tocilizumab in critically ill patients remains limited. We evaluated the associations of first initiation of anakinra or tocilizumab with 28-day and overall in-hospital mortality. Methods: This single-center retrospective ICU cohort included adults with severe COVID-19. During hospital days 2–10, daily actions were classified as anakinra initiation, tocilizumab initiation, or control/defer. Calibrated overlap-weighted modified-Poisson models estimated associations with 28-day and overall in-hospital mortality; ferritin-adjusted sensitivity analyses were performed. Results: Of 306 patients, 241 patients contributed 1,297 eligible person-days. Calibration met the prespecified balance criterion for the included covariates, although effective support for tocilizumab initiation remained limited. For 28-day in-hospital mortality, adjusted RRs versus control/defer were 0.99 (95% CI, 0.80–1.22) for anakinra and 0.99 (95% CI, 0.71–1.37) for tocilizumab. No clear associations were identified in the head-to-head comparison or for overall in-hospital mortality; ferritin-adjusted estimates were similar. Conclusions: In this retrospective ICU cohort, neither anakinra nor tocilizumab initiation showed a clear association with 28-day or overall in-hospital mortality. Estimates were imprecise, particularly for tocilizumab, and remain susceptible to residual confounding.
- 2 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0357671
Open AccessComparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study
Background: Interleukin-1 and interleukin-6 blockade have been widely used in severe COVID-19, but comparative real-world evidence regarding anakinra and tocilizumab in critically ill patients remains limited. We evaluated the associations of first initiation of anakinra or tocilizumab with 28-day and overall in-hospital mortality. Methods: This single-center retrospective ICU cohort included adults with severe COVID-19. During hospital days 2–10, daily actions were classified as anakinra initiation, tocilizumab initiation, or control/defer. Calibrated overlap-weighted modified-Poisson models estimated associations with 28-day and overall in-hospital mortality; ferritin-adjusted sensitivity analyses were performed. Results: Of 306 patients, 241 patients contributed 1,297 eligible person-days. Calibration met the prespecified balance criterion for the included covariates, although effective support for tocilizumab initiation remained limited. For 28-day in-hospital mortality, adjusted RRs versus control/defer were 0.99 (95% CI, 0.80–1.22) for anakinra and 0.99 (95% CI, 0.71–1.37) for tocilizumab. No clear associations were identified in the head-to-head comparison or for overall in-hospital mortality; ferritin-adjusted estimates were similar. Conclusions: In this retrospective ICU cohort, neither anakinra nor tocilizumab initiation showed a clear association with 28-day or overall in-hospital mortality. Estimates were imprecise, particularly for tocilizumab, and remain susceptible to residual confounding.
- 21 May 2026
- Published by Wiley in Hemodialysis International
- Vol. 30 (4) , 765-772
Medium Cut‐Off Versus High‐Flux Dialyzers and Changes in Beck Depression Inventory Scores in Maintenance Hemodialysis: An Exploratory Observational Study
Introduction: Depression is prevalent in maintenance hemodialysis patients and is influenced by the interplay of physical and mental health. Rather than a direct antidepressant effect of dialyzer membrane type, improved clearance of middle and large uremic solutes may alleviate uremia‐related symptoms that indirectly influence mood and quality of life. Methods: This prospective observational study compared changes in Beck Depression Inventory (BDI) scores over 6 months between thrice‐weekly hemodialysis patients treated with Theranova‐400 or FX80 dialyzers. Results: Fifty participants were included (Theranova‐400/FX80: 25/25; median age 52.5 [27.7] years; 27 females; dialysis vintage 60 [86] months). The reduction in BDI scores did not differ significantly between the two groups ( p = 0.203). In the within‐group analysis, a significant decline was observed in the FX80 arm (−4.72 ± 6.62, p = 0.003) but not in the Theranova‐400 arm (−3.20 ± 10.3, p = 0.199). However, in the subgroup of patients with baseline BDI scores > 14, both dialyzer groups showed statistically significant decreases in BDI scores (FX80: 24.7 ± 7.3 to 16.5 ± 6.6, p = 0.016; Theranova‐400: 24.1 ± 8.4 to 14.8 ± 10, p = 0.037). Conclusion: In this exploratory observational study, BDI scores decreased over 6 months in both groups; however, between‐group change in BDI did not differ significantly. These findings do not support a dialyzer‐specific antidepressant effect of Theranova‐400 compared with FX80. Within‐group changes, particularly in the FX80 arm, should be interpreted cautiously considering possible repeated‐measurement effects, regression to the mean, and unmeasured confounding. Future studies should evaluate whether changes in uremic symptom burden mediate mood‐related scores.
- 21 May 2026
- Published by Wiley in Hemodialysis International
- Vol. 30 (4) , 765-772
Medium Cut‐Off Versus High‐Flux Dialyzers and Changes in Beck Depression Inventory Scores in Maintenance Hemodialysis: An Exploratory Observational Study
Introduction: Depression is prevalent in maintenance hemodialysis patients and is influenced by the interplay of physical and mental health. Rather than a direct antidepressant effect of dialyzer membrane type, improved clearance of middle and large uremic solutes may alleviate uremia‐related symptoms that indirectly influence mood and quality of life. Methods: This prospective observational study compared changes in Beck Depression Inventory (BDI) scores over 6 months between thrice‐weekly hemodialysis patients treated with Theranova‐400 or FX80 dialyzers. Results: Fifty participants were included (Theranova‐400/FX80: 25/25; median age 52.5 [27.7] years; 27 females; dialysis vintage 60 [86] months). The reduction in BDI scores did not differ significantly between the two groups ( p = 0.203). In the within‐group analysis, a significant decline was observed in the FX80 arm (−4.72 ± 6.62, p = 0.003) but not in the Theranova‐400 arm (−3.20 ± 10.3, p = 0.199). However, in the subgroup of patients with baseline BDI scores > 14, both dialyzer groups showed statistically significant decreases in BDI scores (FX80: 24.7 ± 7.3 to 16.5 ± 6.6, p = 0.016; Theranova‐400: 24.1 ± 8.4 to 14.8 ± 10, p = 0.037). Conclusion: In this exploratory observational study, BDI scores decreased over 6 months in both groups; however, between‐group change in BDI did not differ significantly. These findings do not support a dialyzer‐specific antidepressant effect of Theranova‐400 compared with FX80. Within‐group changes, particularly in the FX80 arm, should be interpreted cautiously considering possible repeated‐measurement effects, regression to the mean, and unmeasured confounding. Future studies should evaluate whether changes in uremic symptom burden mediate mood‐related scores.
- Open Access
- 2 August 2022
- Published by Akdeniz University in Akdeniz Medical Journal
- Vol. 10 (1) , 70-77
Evaluation of the Effect of Prone Position in Intubated and Non-intubated Covid 19 Patients
Objective: This study was conducted to evaluate the effect of prone position (PP) applied to intubated, and non-intubated patients followed up with COVID-19 in the intensive care unit (ICU). Method: 108 COVID-19 patients followed in a single ICU were included in the study. PP was applied to the patients. The effect of PP on outcome parameters such as oxygenation, development of complications, length of hospital stay and mortality was evaluated. Results: Baseline PaO2:FiO2 ratio significantly increased after PP was applied to the intubated group on the 1st day, and the increase continued after the supine position (p 0.05). After the positioning on the 3rd day, when the intubated group was placed in the supine position after PP, there was an increase in the PaO2:FiO2 ratio, and this increase was statistically significant (p 0.05). Conclusions: PP improved oxygenation in the intubated group but was ineffective in reducing the length of hospital stay, complication, and mortality rates. Besides, in the non-intubated group, it is an effective method that improves oxygenation, delays intubation, and reduces complication development and mortality rates.
- 2 August 2022
- Published by Akdeniz University in Akdeniz Medical Journal
- Vol. 10 (1) , 70-77
Open AccessEvaluation of the Effect of Prone Position in Intubated and Non-intubated Covid 19 Patients
Objective: This study was conducted to evaluate the effect of prone position (PP) applied to intubated, and non-intubated patients followed up with COVID-19 in the intensive care unit (ICU). Method: 108 COVID-19 patients followed in a single ICU were included in the study. PP was applied to the patients. The effect of PP on outcome parameters such as oxygenation, development of complications, length of hospital stay and mortality was evaluated. Results: Baseline PaO2:FiO2 ratio significantly increased after PP was applied to the intubated group on the 1st day, and the increase continued after the supine position (p 0.05). After the positioning on the 3rd day, when the intubated group was placed in the supine position after PP, there was an increase in the PaO2:FiO2 ratio, and this increase was statistically significant (p 0.05). Conclusions: PP improved oxygenation in the intubated group but was ineffective in reducing the length of hospital stay, complication, and mortality rates. Besides, in the non-intubated group, it is an effective method that improves oxygenation, delays intubation, and reduces complication development and mortality rates.